Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort
| Autor: | Félix Gutierrez, Sergio Padilla, Mar Masiá, José A Iribarren, Santiago Moreno, Pompeyo Viciana, Leopoldo Muñoz, José L Gómez Sirvent, Francesc Vidal, José López-Aldeguer, José R Blanco, Manuel Leal, María Angeles Rodríguez-Arenas, Santiago Perez Hoyos, CoRIS-MD |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Science Immunology HIV Infections Kaplan-Meier Estimate Cohort Studies Acquired immunodeficiency syndrome (AIDS) Antiretroviral Therapy Highly Active Internal medicine medicine Humans Proportional Hazards Models Multidisciplinary Proportional hazards model business.industry Mortality rate Hazard ratio Infectious Diseases/HIV Infection and AIDS Prognosis medicine.disease Confidence interval CD4 Lymphocyte Count Surgery Regimen Treatment Outcome Spain Cohort HIV-1 RNA Viral Medicine Female business Follow-Up Studies Research Article Cohort study |
| Zdroj: | PLoS ONE, Vol 1, p e89 (2006) PLoS ONE |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0000089 |
| Popis: | BackgroundLimited information exists on long-term prognosis of patients with sustained virologic response to antiretroviral therapy. We aimed to assess predictors of unfavorable clinical outcome in patients who maintain viral suppression with HAART.MethodsUsing data collected from ten clinic-based cohorts in Spain, we selected all antiretroviral-naive adults who initiated HAART and maintained plasma HIV-1 RNA levels ResultsOf 2,613 patients who started HAART, 757 fulfilled the inclusion criteria. 61% of them initiated a protease inhibitor-based HAART regimen, 29.7% a nonnucleoside reverse-transcriptase inhibitor-based regimen, and 7.8% a triple-nucleoside regimen. During 2,556 person-years of follow-up, 22 (2.9%) patients died (mortality rate 0.86 per 100 person-years), and 40 (5.3%) died or developed a new AIDS-defining event. The most common causes of death were neoplasias and liver failure. Mortality was independently associated with a CD4-T cell response ConclusionsPatients with sustained virologic response on HAART have a low mortality rate over time. Long-term outcome of these patients is driven by immunologic response at the end of the first year of therapy and age at the time of HAART initiation, but not by the initial antiretroviral regimen selected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|